Molecular subtyping of colorectal cancer: Recent progress, new challenges and emerging opportunities.
Molecular subtyping of colorectal cancer: Recent progress, new challenges and emerging opportunities.
复制标题
DOI：
10.1016/j.semcancer.2018.05.002
复制
发表时间：
2019-04
影响因子：
14.5
通讯作者：
Wang X
中科院分区：
文献类型：
--
作者：
Wang W;Kandimalla R;Huang H;Zhu L;Li Y;Gao F;Goel A;Wang X
结直肠癌（CRC）是全球癌症相关死亡的主要原因之一。与许多其他恶性肿瘤类似，CRC是一种异质性疾病，这使得优化治疗方式以降低与该疾病相关的发病率和死亡率成为临床挑战。更精确地了解区分结直肠肿瘤患者的生物学特性，特别是在其临床特征方面，是实现更稳健的靶向药物设计和实施个体化治疗的关键要求。近几十年来，广泛的研究报道了不同的CRC亚型，肿瘤异质性以突变为中心。然而，最近，范式已经转向基于转录组的分类，由六个独立的CRC分类代表。2015年，结直肠癌亚型联盟报告了四种共有分子亚型（CMS）的鉴定，为CRC提供了迄今为止最强大的分类系统。在这篇综述中，我们总结了CRC分类方法的历史时间轴，讨论了它们的显著特征和潜在的局限性，可能需要在不久的将来进一步完善。换句话说，尽管最近取得了令人鼓舞的进展，但几个主要挑战阻止了从CMS收集的分子知识转化为临床。在此，我们总结了其中一些潜在的挑战，并讨论了相关领域目前出现的令人兴奋的新机遇。我们相信，基础研究人员，生物信息学家和临床医生之间的密切合作对于应对这些挑战至关重要，并最终为CRC分型进入常规临床实践铺平道路，因为我们迎来了个性化医疗时代。
Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide. Similar to many other malignancies, CRC is a heterogeneous disease, making it a clinical challenge for optimization of treatment modalities in reducing the morbidity and mortality associated with this disease. A more precise understanding of the biological properties that distinguish patients with colorectal tumors, especially in terms of their clinical features, is a key requirement towards a more robust, targeted-drug design, and implementation of individualized therapies. In the recent decades, extensive studies have reported distinct CRC subtypes, with a mutation-centered view of tumor heterogeneity. However, more recently, the paradigm has shifted towards transcriptome-based classifications, represented by six independent CRC taxonomies. In 2015, the colorectal cancer subtyping consortium reported the identification of four consensus molecular subtypes (CMSs), providing thus far the most robust classification system for CRC. In this review, we summarize the historical timeline of CRC classification approaches; discuss their salient features and potential limitations that may require further refinement in near future. In other words, in spite of the recent encouraging progress, several major challenges prevent translation of molecular knowledge gleaned from CMSs into the clinic. Herein, we summarize some of these potential challenges and discuss exciting new opportunities currently emerging in related fields. We believe, close collaborations between basic researchers, bioinformaticians and clinicians are imperative for addressing these challenges, and eventually paving the path for CRC subtyping into routine clinical practice as we usher into the era of personalized medicine.
登录
查看更多内容
影响因子：
29.4
作者：
Boland CR;Goel A
通讯作者：
Goel A
影响因子：
3.8
作者：
Ang PW;Loh M;Liem N;Lim PL;Grieu F;Vaithilingam A;Platell C;Yong WP;Iacopetta B;Soong R
通讯作者：
Soong R
影响因子：
16.6
作者：
Cantini L;Isella C;Petti C;Picco G;Chiola S;Ficarra E;Caselle M;Medico E
通讯作者：
Medico E
DOI：
10.1002/path.5051
发表时间：
2018-05
期刊：
The Journal of pathology
影响因子：
--
作者：
Alderdice M;Richman SD;Gollins S;Stewart JP;Hurt C;Adams R;McCorry AM;Roddy AC;Vimalachandran D;Isella C;Medico E;Maughan T;McArt DG;Lawler M;Dunne PD
通讯作者：
Dunne PD
影响因子：
8
作者：
Blandino, G;Levine, AJ;Oren, M
通讯作者：
Oren, M